|
|
Volumn 16 Suppl 2, Issue , 2011, Pages 14-22
|
|
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BENZENESULFONIC ACID DERIVATIVE;
BEVACIZUMAB;
DRUG DERIVATIVE;
EVEROLIMUS;
INDOLE DERIVATIVE;
INTERLEUKIN 2;
MONOCLONAL ANTIBODY;
PYRIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
RAPAMYCIN;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
CLINICAL TRIAL (TOPIC);
DISEASE FREE SURVIVAL;
HUMAN;
IMMUNOTHERAPY;
KIDNEY CARCINOMA;
KIDNEY TUMOR;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
MULTIMODALITY CANCER THERAPY;
REVIEW;
TREATMENT OUTCOME;
URINE;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BENZENESULFONATES;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS AS TOPIC;
COMBINED MODALITY THERAPY;
DISEASE-FREE SURVIVAL;
HUMANS;
IMMUNOTHERAPY;
INDOLES;
INTERFERON-ALPHA;
INTERLEUKIN-2;
KIDNEY NEOPLASMS;
MOLECULAR TARGETED THERAPY;
PYRIDINES;
PYRROLES;
SIROLIMUS;
TREATMENT OUTCOME;
|
|
EID: 79955845255
PISSN: None
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2011-S2-14 Document Type: Review |
|
Times cited : (145)
|
|
References (0)
|
